American Chemical Society

MetasTx LLC Celebrates Dr. David Crich’s Achievement of the 2024 James Flack Norris Award in Physical Organic Chemistry

Retrieved on: 
Monday, March 25, 2024
Physical organic chemistry, ACS, Cancer, Research, American Chemical Society, Science

PITTSBURGH, March 25, 2024 (GLOBE NEWSWIRE) -- MetasTx LLC , an innovator in the development of novel cancer treatment agents, proudly congratulates Dr. David Crich, GEORGIA RESEARCH ALLIANCE AND DAVID CHU EMINENT SCHOLAR IN DRUG DESIGN and Head of Chemistry at MetasTx, for being honored with the prestigious 2024 James Flack Norris Award in Physical Organic Chemistry.

Key Points: 
  • PITTSBURGH, March 25, 2024 (GLOBE NEWSWIRE) -- MetasTx LLC , an innovator in the development of novel cancer treatment agents, proudly congratulates Dr. David Crich, GEORGIA RESEARCH ALLIANCE AND DAVID CHU EMINENT SCHOLAR IN DRUG DESIGN and Head of Chemistry at MetasTx, for being honored with the prestigious 2024 James Flack Norris Award in Physical Organic Chemistry.
  • Dr. Crich’s extensive body of work, particularly his revolutionary methods for stereoselective glycosylation, has significantly advanced our understanding of organic chemistry's complex mechanisms.
  • The award highlights Dr. Crich's sustained commitment to the study and application of mechanistic organic chemistry, marking a milestone in his career.
  • His pioneering work in hydroxylamine-based anticancer antibiotics and the application of physical organic principles in medicinal chemistry are especially noteworthy.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Retrieved on: 
Thursday, March 21, 2024
MGH, Eating, Obesity, Oxytocin, Patient, Weight loss, Binge eating disorder, University, Prader–Willi syndrome, Tonix Pharmaceuticals, IND, American Chemical Society, Magnesium, Adolescence, Insulin resistance, Hospital, Safety, ACS, Social anxiety disorder, Spectrum, Pain, Nasal administration, Poster

CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at the American Chemistry Society (ACS) Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana. A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com.

Key Points: 
  • A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com .
  • The poster presentation titled, Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations, describes the discovery and characterization of novel oxytocin analogues that are candidate treatments for craniofacial pain, excessive eating (including Prader Willi Syndrome), and endocrinological conditions including bone health in autism and insulin resistance.
  • “Intranasal oxytocin has several potential therapeutic applications,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • The Phase 2 ‘STROBE’ study at MGH is investigating the efficacy and safety of TNX-1900 as a novel therapeutic agent to reduce binge eating frequency in adults with binge-eating disorder.

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Retrieved on: 
Wednesday, March 20, 2024
Cancer, Drug discovery, Patient, SAN, Inflammation, Poster, Biochemistry, Clinical trial, Therapy, Paclitaxel, Safety, ACS, American Chemical Society, Lymphoma, Pharmaceutical industry

SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA. This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.

Key Points: 
  • This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.
  • “Today’s presentation at the ACS meeting showcases Nurix’s innovative combination of structure-based-drug-design and industry-leading expertise in the biochemistry of E3 ligases,” noted Gwenn Hansen, Ph.D., Nurix’s chief scientific officer.
  • This mechanism of action is notable because CBL-B lacks a classic enzymatic active site binding pocket, preventing typical inhibitor design and thereby requiring a novel drug discovery approach.
  • A copy of the presentation is available on the Posters and Presentations section of the scientific resources page of Nurix’s website.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, Depression, Conference, American Chemical Society, Patent, Acceleration, Partnership, HERG, Patient, CNS, Journal, Anxiety, IND, Chemical substance, Addiction, Safety, Therapy, Arthropathy, Medicinal chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
  • “The fourth quarter of 2023 and early 2024 was a significant period for Enveric, highlighted by the selection of EB-003 as our lead development candidate.
  • Continued to strengthen our intellectual property portfolio, receiving ten patent issuances from the United States Patent and Trademark Office.
  • The gross proceeds to the Company from the two warrant exercises totaled approximately $4.5 million.

Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting

Retrieved on: 
Wednesday, March 20, 2024
Health, Technology, Health Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Safety, ACS, Pharmacokinetics, BTK, Therapy, MALT1, Lymphoid leukemia, American Chemical Society, Pharmaceutical industry

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.
  • The oral presentation provided an overview of how Schrödinger leveraged its computational approaches at scale to discover SGR-1505.
  • Reaching a development candidate can take three to six years and typically involves synthesizing up to 5,000 molecules per program.
  • Schrödinger recently completed a Phase 1 study showing that SGR-1505 was well tolerated in a Phase 1 study of 73 healthy volunteers.

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Stromal cell, Amgen, American Chemical Society, University, Cornell University, Patient, Medicinal chemistry, Indiana University, Whitehead Institute, Doctor of Philosophy, Therapy, Drug development, Pharmacy, Division, Molecular biology, Takeda Oncology, Ironwood Pharmaceuticals, Pharmaceutical industry

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

YourChoice Therapeutics Scientific Advisory Board member updates phase 1a study for male birth control candidate at ACS Spring 24

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Other Health, Health, General Health, Healthcare Reform, Pharmaceutical, Other Science, Research, Public Policy, Government, Science, Clinical Trials, Vitamin A, Mouse, University, Doctor of Philosophy, Trial of the century, Woman, Male, Therapy, Safety, ACS, Pharmacokinetics, American Chemical Society, Birth control

YourChoice Therapeutics, a San Francisco biotech startup developing the first hormone-free male birth control pill, announced today that Gunda Georg, YCT-529’s co-inventor, provided an update on its phase 1a clinical study for the first hormone-free male birth control pill, YCT-529, at the American Chemical Society (ACS) 2024 Spring Meeting.

Key Points: 
  • YourChoice Therapeutics, a San Francisco biotech startup developing the first hormone-free male birth control pill, announced today that Gunda Georg, YCT-529’s co-inventor, provided an update on its phase 1a clinical study for the first hormone-free male birth control pill, YCT-529, at the American Chemical Society (ACS) 2024 Spring Meeting.
  • The phase 1a study investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of single, ascending oral doses of YCT-529 in 16 participants.
  • I’m pleased to be a part of that future.”
    YCT-529 is a hormone-free birth control candidate currently under investigation.
  • “Men and women want more birth control options, and they want them to be hormone-free,” said Akash Bakshi, co-founder and CEO of YourChoice Therapeutics.

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ODD, Cancer, Research, PRMT5, Brain, Mutation, BRCA, NSCLC, NYU Langone Health, Breast, General counsel, Patient, GBM, Orphan, Collaboration, DNA, DevOps, MTAP, Sarcoma, Head, MTA, AACR, Glioblastoma, Clinical trial, PARP, Therapy, Drug development, ATM, ACS, Safety, Pharmacokinetics, Carcinoma, Corporate governance, FDA, American Chemical Society, Food, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
  • “In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials.
  • The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG462 in December 2023 for the treatment of soft tissue sarcomas.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition

Retrieved on: 
Tuesday, March 26, 2024
Solvent, CDMO, American Chemical Society, Biocatalysis, PMI, Carbon footprint, Decarboxylation, Hydrogenation, Green Chemistry Award, Chemistry, Amination, Safety, ACS, GCI, Fine chemical

This esteemed award, marking the company's second consecutive win among global CDMO companies, is a testament to PharmaBlock's persistent commitment to green chemistry and its unwavering efforts in crafting innovative, sustainable solutions for the pharmaceutical industry.

Key Points: 
  • This esteemed award, marking the company's second consecutive win among global CDMO companies, is a testament to PharmaBlock's persistent commitment to green chemistry and its unwavering efforts in crafting innovative, sustainable solutions for the pharmaceutical industry.
  • These compounds are vital in the pharmaceutical industry and serve as raw materials or key intermediates for many marketed drugs.
  • PharmaBlock has been developing a comprehensive suite of solutions, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, immobilized catalysis, etc.
  • "We are thrilled to receive the CMO Excellence in Green Chemistry Award for the second consecutive year.